重组人促血小板生成素对白血病化疗后血小板减少症的疗效研究

Effect of Recombinant Human Thrombopoietin on Thrombocytopenia after Chemotherapy in Leukemia

目的分析重组促血小板生成素(rhTPO)对于白血病化疗后血小板减少症的临床疗效及安全性。方法选取2017年1月至2018年12月期间在浙江大学医学院附属第一医院接受化疗的白血病患者56例,随机分为对照组及观察组,对照组采取重组人白介素-11治疗(rhIL-11),观察组采取rhTPO治疗,比较两组临床疗效及安全性。结果观察组患者化疗12 d及24 d后患者的血小板(BPC)水平均显著高于对照组(P<0.05);观察组血小板<50×109/L、恢复至70×109/L以及100×109/L所需时间均显著短于对照组(P<0.05);观察组不良反应发生率为7.1%,对照组为46.4%,组间差异明显(P>0.05)。结论白血病患者化疗后采取rhTPO治疗可快速恢复血小板计数水平,临床安全性高,值得推荐使用。

Objective To analyze the clinical efficacy and safety of recombinant thrombopoietin(rhTPO)for thrombocytopenia after chemotherapy in leukemia.Methods 56 leukemia patients who received chemotherapy in The First Affiliated Hospital of Zhejiang University Medical College from January 2017 to December 2018 were randomly divided into the control group and the observation group.The control group was treated with rhIL-11 and the observation group was treated with rhTPO to compare the clinical efficacy and safety of the two groups.Results The level of platelet(BPC)in the observation group was significantly higher than that in the control group(P<0.05)12 days after chemotherapy and 24 days after chemotherapy;the time required for platelet in the observation group to be<50×109/L,recovered to 70×109/L and 100×109/l was significantly shorter than that in the control group(P<0.05);the incidence of adverse reactions in the observation group was 7.1%,46.4%in the control group,and the difference between the groups was significant(P>0.05).Conclusion rhTPO can recover the platelet count rapidly after chemotherapy in patients with leukemia,which has high clinical safety.